DELCATH SYSTEMS INC DCTH

December 20, 2022 - 9:19am EST by

member

						2022	2023
Price:		3.55		EPS		0	0
Shares Out. (in M):		10		P/E		0	0
Market Cap (in $M):		37		P/FCF		0	0
Net Debt (in $M):		2		EBIT		0	0
TEV (in $M):		39		TEV/EBIT		0	0

* Idea not eligible for membership requirements

Description

Sign up or Log In

Sign up for free guest access to view investment ideas with a 45-day delay and read the full report.

Log in to read the full report.

1 show sort by

#	AUTHOR DATE SUBJECT
2	member 9/05/23 7:33PM Delcath (DCTH) Update
On August 14th, the US Food and Drug Administration (FDA) approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM), a rare form of cancer that affects... login to read the rest view available tags
1	member 5/30/23 8:10PM Delcath (DCTH-$7.70): Update
On March 27, the company announced that the FDA accepted its resubmitted new drug application (NDA) for the HEPZATO Kit for certain liver-dominant eye cancer. The FDA has issued August 14, 2023, as the PDUFA... login to read the rest 1 view available tags

load more messages